MeSH Terms,count
Humans,179
Leukemia,139
Acute,121
Myeloid,120
Aged,104
Female,72
Male,70
Adult,63
Middle Aged,62
Antineoplastic Combined Chemotherapy Protocols,59
,48
Heterocyclic,38
Bridged Bicyclo Compounds,38
Hematopoietic Stem Cell Transplantation,37
Treatment Outcome,36
80 and over,33
Sulfonamides,33
Azacitidine,32
Antineoplastic Agents,32
Mice,26
Myelodysplastic Syndromes,21
Tumor,21
Young Adult,21
Neoplasm,19
Cytarabine,19
Animals,18
Transplantation,16
Prognosis,16
Remission Induction,15
Cell Line,15
Receptors,15
Mutation,14
Child,14
Hematologic Neoplasms,14
Immunotherapy,14
Recurrence,13
Decitabine,13
T-Lymphocytes,13
Neoplasm Recurrence,12
Chronic,12
Local,12
Adoptive,12
Antibodies,11
Adolescent,11
Graft vs Host Disease,11
Prospective Studies,11
Randomized Controlled Trials as Topic,10
Retrospective Studies,10
Xenograft Model Antitumor Assays,10
Drug Resistance,10
Homologous,10
Neoplasms,9
Chimeric Antigen,9
fms-Like Tyrosine Kinase 3,9
Residual,9
Monoclonal,9
Myelomonocytic,8
Nucleophosmin,8
Quality of Life,8
Myeloproliferative Disorders,7
Biomarkers,7
Clinical Trials,7
Daunorubicin,7
Proto-Oncogene Proteins,7
Pyrimidines,7
Cell Proliferation,7
Tumor Suppressor Protein p53,6
Precursor Cell Lymphoblastic Leukemia-Lymphoma,6
Multiple Myeloma,6
SCID,6
Proto-Oncogene Proteins c-bcl-2,6
Genetic,6
Dose-Response Relationship,6
Drug,6
Protein Kinase Inhibitors,6
COVID-19,6
Disease Susceptibility,6
Pyrroles,5
Infant,5
Histone-Lysine N-Methyltransferase,5
Maximum Tolerated Dose,5
Indoles,5
Combined Modality Therapy,5
Disease Management,5
Maintenance Chemotherapy,5
Pyrazoles,5
Sialic Acid Binding Ig-like Lectin 3,5
Phenylurea Compounds,5
Pilot Projects,5
Humanized,5
Immunological,5
Molecular Targeted Therapy,4
Mastocytosis,4
Systemic,4
Neoplastic,4
Risk Assessment,4
Phase I as Topic,4
Gene Expression Regulation,4
Feasibility Studies,4
Preschool,4
Isocitrate Dehydrogenase,4
Triazines,4
Apoptosis,4
Antigen,4
Vidarabine,4
T-Cell,4
B-Cell,4
Transplantation Conditioning,4
Clinical Decision-Making,4
Drug Administration Schedule,3
Positron Emission Tomography Computed Tomography,3
Follow-Up Studies,3
Antigens,3
Cytokine Release Syndrome,3
Cyclopentanes,3
Chronic Disease,3
Second Primary,3
Cyclophosphamide,3
Natural,3
Allografts,3
Disease-Free Survival,3
Myeloid-Lymphoid Leukemia Protein,3
SARS-CoV-2,3
Oncogene Proteins,3
Fusion,3
Proteomics,3
Neoplasm Proteins,3
Myeloid Cell Leukemia Sequence 1 Protein,3
Inbred NOD,3
Longitudinal Studies,3
Immunoconjugates,3
Haploidentical,3
Autologous,3
Gemtuzumab,3
Protein Binding,3
Hydrazines,3
BCR-ABL Positive,3
Interleukin-3 Receptor alpha Subunit,3
Cultured,3
Tumor Cells,3
Killer Cells,3
Lymphocytic,3
Benzimidazoles,3
Myelogenous,3
Benzamides,3
Aclarubicin,3
Nuclear Proteins,3
Thrombocytopenia,3
Aminopyridines,3
Cyclin-Dependent Kinase 9,2
Tryptases,2
Inherited,2
Idarubicin,2
Depression,2
Anxiety,2
Chromosome Aberrations,2
Cytogenetic Analysis,2
Homoharringtonine,2
Decision Making,2
Pyrazines,2
Aniline Compounds,2
Caregivers,2
Communication,2
Signal Transduction,2
Oligopeptides,2
Protein Serine-Threonine Kinases,2
Neoplastic Stem Cells,2
Anti-Infective Agents,2
Fluorodeoxyglucose F18,2
Positron-Emission Tomography,2
Models,2
Uridine,2
Carcinoma,2
Indazoles,2
Imidazoles,2
Stem Cells,2
Nuclear Pore Complex Proteins,2
Antibiotics,2
Anthracyclines,2
Antineoplastic,2
China,2
Phase II as Topic,2
Aldehyde Dehydrogenase,2
Busulfan,2
Sarcoma,2
Promoter Regions,2
Aminoglycosides,2
Induction Chemotherapy,2
Leukocytes,2
Mononuclear,2
HEK293 Cells,2
Gene Expression Profiling,2
Bone Neoplasms,2
Biosynthetic Pathways,2
Activating Transcription Factor 4,2
Transcription,2
Pyridazines,2
Serine,2
RNA Interference,2
Ewing,2
HLA-A2 Antigen,2
WT1 Proteins,2
Granulocyte Colony-Stimulating Factor,2
Cladribine,2
RNA-Binding Protein EWS,2
Proto-Oncogene Protein c-fli-1,2
Tyrosine Kinase Inhibitors,2
Epigenesis,2
Cancer Vaccines,2
Bone Marrow Transplantation,2
Bispecific,2
CD3 Complex,2
Oxides,2
Fatigue,2
Receptor Tyrosine Kinase-like Orphan Receptors,2
Blood Coagulation Disorders,2
Blood Platelet Disorders,2
Core Binding Factor Alpha 2 Subunit,2
Arsenic Trioxide,2
Multicenter Studies as Topic,2
Critical Care,2
Critical Illness,2
Nucleosomes,2
Dendritic Cells,2
Nerve Growth Factor,2
Methotrexate,2
Survival Rate,2
Bone Marrow,2
Tacrolimus,2
Quinuclidines,2
Promyelocytic,2
Telemedicine,2
Arsenicals,2
Tretinoin,2
Mycophenolic Acid,2
CD19,2
Lymphoma,2
Juvenile,2
Pandemics,1
Bayes Theorem,1
Pyridones,1
Pyrimidinones,1
Age Factors,1
Cytomegalovirus,1
CD8-Positive T-Lymphocytes,1
Vaccinia,1
Cytomegalovirus Infections,1
Antiviral Agents,1
Vaccination,1
Tissue Donors,1
Transplant Recipients,1
COVID-19 Vaccines,1
Adoptive Transfer,1
Mantle-Cell,1
Large B-Cell,1
Diffuse,1
Tumor Microenvironment,1
Aminobenzoates,1
Drug Delivery Systems,1
Knockout,1
Calicheamicins,1
Ascorbic Acid,1
Dioxygenases,1
DNA-Binding Proteins,1
Genomics,1
Germ Cells,1
Drug Therapy,1
Combination,1
Proteins,1
Pyridines,1
Cell Division,1
Phase III as Topic,1
Azepines,1
Preoperative Exercise,1
Cardiotoxicity,1
Doxorubicin,1
Patient Reported Outcome Measures,1
Immunosuppressive Agents,1
Bronchiolitis Obliterans Syndrome,1
Unrelated Donors,1
Hispanic or Latino,1
Cancer Survivors,1
Parenting,1
Parents,1
Learning,1
White,1
Receptor,1
Anthracenes,1
Biopsy,1
Retreatment,1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma,1
Outpatients,1
Agammaglobulinaemia Tyrosine Kinase,1
Aurora Kinases,1
Cell Cycle,1
Disease Models,1
Animal,1
Protein-Tyrosine Kinases,1
Decision Support Techniques,1
Health Knowledge,1
Attitudes,1
Practice,1
Knowledge,1
Sirolimus,1
Cytokines,1
K562 Cells,1
Phenotype,1
Central Nervous System Neoplasms,1
Injections,1
Spinal,1
Myeloablative Agonists,1
Cytotoxicity,1
Immunologic,1
United Kingdom,1
Registries,1
High-Throughput Nucleotide Sequencing,1
Genetic Testing,1
Peptides,1
Cytotoxic,1
Triazoles,1
Niacinamide,1
Angiogenesis Inhibitors,1
Fusion Proteins,1
bcr-abl,1
Philadelphia Chromosome,1
Cognitive Behavioral Therapy,1
B7-H1 Antigen,1
Programmed Cell Death 1 Receptor,1
Asparaginase,1
Polyethylene Glycols,1
Amino Acids,1
Japan,1
Homeodomain Proteins,1
Biological,1
Mobile Applications,1
Proto-Oncogene Proteins c-jun,1
Anemia,1
Nausea,1
Clinical Protocols,1
Research Design,1
Staurosporine,1
Donor Selection,1
Reproducibility of Results,1
Clone Cells,1
Gene Rearrangement,1
Spiro Compounds,1
Aldehyde Dehydrogenase 1 Family,1
Mitochondrial,1
Reactive Oxygen Species,1
Retinal Dehydrogenase,1
Hydroxamic Acids,1
RNA Splicing Factors,1
RNA Splicing,1
Pneumonia,1
Immune Checkpoint Inhibitors,1
Music Therapy,1
Stem Cell Transplantation,1
Clinical Trials as Topic,1
United States,1
Stomach Neoplasms,1
Phytolaccaceae,1
Adenosine Triphosphatases,1
HCT116 Cells,1
Isothiocyanates,1
Sulfoxides,1
Valosin Containing Protein,1
CD7,1
Single-Domain Antibodies,1
Pathologic Complete Response,1
Sorafenib,1
Actinium,1
Bendamustine Hydrochloride,1
Incidence,1
Graft Rejection,1
Fecal Microbiota Transplantation,1
Gastrointestinal Microbiome,1
Double-Blind Method,1
Feces,1
Alkylating,1
Kaplan-Meier Estimate,1
Salvage Therapy,1
Acute Disease,1
Interleukin-2,1
Mitoxantrone,1
Neoplasm Staging,1
Plasma Cells,1
Ursodeoxycholic Acid,1
Disease Progression,1
Purpura,1
Thrombocytopenic,1
Proteasome Endopeptidase Complex,1
Protein Conformation,1
Protein Processing,1
Post-Translational,1
Proteolysis,1
Small Molecule Libraries,1
Stress,1
Physiological,1
TOR Serine-Threonine Kinases,1
U937 Cells,1
Ubiquitin-Protein Ligases,1
Ubiquitination,1
Physician-Patient Relations,1
Patient-Centered Care,1
Idiopathic,1
Cohort Studies,1
Thrombopoietin,1
Recombinant Fusion Proteins,1
Fc,1
Proportional Hazards Models,1
In Situ Hybridization,1
Fluorescence,1
Peripheral Blood Stem Cell Transplantation,1
Minor Histocompatibility Antigens,1
Databases,1
Factual,1
Odds Ratio,1
Placebo Effect,1
Poly(ADP-ribose) Polymerase Inhibitors,1
Advance Care Planning,1
Denmark,1
Empathy,1
Terminal Care,1
Antimony,1
Antiparasitic Agents,1
Drug Repositioning,1
Temperature,1
Non-Small-Cell Lung,1
Respiratory Insufficiency,1
Sepsis,1
Drug Combinations,1
Acetamides,1
Adaptor Proteins,1
Signal Transducing,1
CRISPR-Cas Systems,1
Isoindoles,1
Molecular,1
Nuclear Factor 45 Protein,1
Nuclear Factor 90 Proteins,1
Peptide Termination Factors,1
Piperidones,1
Lung Neoplasms,1
Drug Evaluation,1
Preclinical,1
Burkitt Lymphoma,1
Inotuzumab Ozogamicin,1
Australia,1
Cost-Benefit Analysis,1
Hematology,1
Tomography,1
X-Ray Computed,1
Lymphocyte Depletion,1
Proto-Oncogene Proteins c-kit,1
Adenosine,1
Cell Cycle Checkpoints,1
Cyclin-Dependent Kinase 2,1
Cyclin-Dependent Kinases,1
Interleukin-1beta,1
Erythropoiesis,1
Precision Medicine,1
Drug-Related Side Effects and Adverse Reactions,1
Febrile Neutropenia,1
Benzothiazoles,1
Proto-Oncogene Proteins c-cbl,1
Exercise,1
Naphthyridines,1
Adenoid Cystic,1
Protein-Arginine N-Methyltransferases,1
Progression-Free Survival,1
